Question 1

What are the differences between the two treatment schedules being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

Question 2

How will this trial affect my current treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

Question 3

What potential side effects should I be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer clinical trial (NCT00118755). Contact the study team or your healthcare provider for specific answers.

What this study is about